HACKENSACK, N.J. and PETACH TIKVAH, Israel, April 14, 2015 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that results from its phase 2a study of NurOwn® in amyotrophic lateral sclerosis (ALS) and additional analyses will be presented at the American Academy of Neurology annual meeting, taking place in Washington D.C. from April 18 to 25, 2015.
BrainStorm's CEO Tony Fiorino, MD, PhD, commented "We are thrilled to have the opportunity to share our results at this prestigious venue, and we look forward to discussing these findings with the medical community."
NurOwn® is an autologous cell therapy in which bone marrow-derived mesenchymal stem cells are expanded and then, under proprietary conditions, induced to secrete several neurotrophic factors known to promote neuronal survival. BrainStorm has completed two clinical trials of these neurotrophic factor-secreting mesenchymal stem cells in Israel, and is currently enrolling a randomized, double-blind, placebo-controlled phase 2 study at three centers in the United States.
The presentation details are as follows:
Poster: P2.059 "Autologous Transplantation of Mesenchymal Stem Cells Secreting Neurotrophic Factors (Nurown™) in ALS: Results of a Phase 2 Clinical Trial"
Session Date/Time: Session P2, Tuesday April 21, 2015, 7:30am to 12:00pm (EDT)
Location: Walter E. Washington Convention Center, Washington, DC
About BrainStorm Cell Therapeutics, Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. For more information, visit the company's website at www.brainstorm-cell.com .
Safe Harbor Statement
Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may," "should," "would," "could," "will," "expect," "likely," "believe," "plan," "estimate," "predict," "potential," and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/brainstorm-cell-therapeutics-to-present-positive-nurown-phase-2a-clinical-data-at-american-academy-of-neurology-annual-meeting-300065388.html
SOURCE BrainStorm Cell Therapeutics Inc.